T1	Limitation 23537 23540	Our
T2	SampleSize 23588 23609	small patient numbers
T3	UnderpoweredStudy 23625 23683	was not powered to detect differences in clinical outcomes
T4	VerySpecificPopulation 23685 23738	Our significant proportion of cardiovascular patients
T5	Limitation 23685 23688	Our
T6	Generalization 23748 23770	limit generalizability
T7	HighLossToFollowUp 24002 24121	Our loss to follow-up for our functional secondary outcomes measured at ICU and hospital discharge was also significant
T8	Limitation 24002 24005	Our
T9	MissingData 24196 24272	data collection on nutrition intake ceased when oral intake commenced in ICU
T10	Limitation 24187 24194	Finally
T11	Limitation 23772 23774	We
T12	ValidityOfMeasurement 23772 23880	We used ‘administration of new antibiotics’ as a surrogate marker for development of infective complications
